# Targacept

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/targacept

- Industry: Biotechnology
- Headquarters: Winston-Salem, US
- Website: www.targacept.com
- Total disclosed funding: $90M
- Latest round: Series B (Mar 19, 2003)
- Investors on record: 19

## About

Targacept is a biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders, focusing on unmet medical needs through targeted receptor modulation.Founded in 1997 in Winston-Salem, US, Targacept specializes in pharmaceutical development, particularly for central nervous system disorders. The firm went public in April 2006, raising USD 45 mn through an IPO. In March 2015, it announced a merger with Catalyst Biosciences, which would form a new entity named Catalyst Biosciences, Inc.Targacept focuses on developing innovative pharmaceutical products aimed at addressing unmet medical needs, particularly in the field of central nervous system disorders. Their core offerings include a range of compounds that target specific receptors to modulate neuronal activity, providing potential therapeutic options for conditions such as depression and cognitive impairment. These products are designed to enhance the efficacy of existing treatments while minimizing side effects, thereby improving patient outcomes. Targacept primarily serves healthcare professionals, hospitals, and specialty pharmacies, catering to patients across North America and Europe who require advanced treatment options for complex neurological conditions. The company’s product line is targeted at both established markets and regions with significant growth potential in the biopharmaceutical sector.In 2014, Targacept reported a revenue of USD 275,000, with an EBITDA loss of USD 28,588,000. The company's revenue model is based on collaboration agreements and licensing deals that allow them to monetize their proprietary research and development efforts. Through partnerships, Targacept provides innovative compounds for further development and commercialization in exchange for milestone payments and royalties on future sales, ensuring the company maintains a robust pipeline of products.Targacept's future growth strategy includes the introduction of new products from its pipeline, with specific launch dates yet to be confirmed. The company plans to expand into new geographic markets, focusing on regions in North America and Europe, leveraging the insights gained from its merger with Catalyst Biosciences. The funds raised from the IPO in April 2006, amounting to USD 45 mn, are expected to support these initiatives, enhancing their research and development capabilities as they work towards launching new therapeutic options.

## Funding rounds

- Series B, Mar 19, 2003, $14M — Academy Funds, Auriga Partners, Burrill & Company, EuclidSR Partners, New Enterprise Associates, Oxford Bioscience Partners, SGAM Private Equity, Easton Capital Investment Group, Advent Venture Partners, Bison Capital Asset Management, Cogene Ventures, CDIB BioScience Venture Management, Icon Ventures, Nomura Asset Management, CDC IXIS, Rock Castle Ventures, Genavent
- Series B, Dec 5, 2002, $46M — Academy Funds, Auriga Partners, Burrill & Company, EuclidSR Partners, New Enterprise Associates, SGAM Private Equity, Easton Capital Investment Group, Advent Venture Partners, CDIB BioScience Venture Management, Nomura Asset Management, CDC IXIS, Genavent
- Series A, Aug 24, 2000, $30M — Auriga Partners, Burrill & Company, EuclidSR Partners, SGAM Private Equity, Advent Venture Partners, CDC IXIS, Aventis Capital, Longleaf Venture Fund

## Investors

- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series A, Series B
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A, Series B
- EuclidSR Partners (https://capitalatlas.ai/funds/euclidsr-partners) — Series A, Series B
- SGAM Private Equity (https://capitalatlas.ai/funds/sgam-private-equity) — Series A, Series B
- Advent Venture Partners (https://capitalatlas.ai/funds/advent-venture-partners) — Series A, Series B
- CDC IXIS — Series A, Series B
- Aventis Capital — Series A
- Longleaf Venture Fund (https://capitalatlas.ai/funds/longleaf-venture-fund) — Series A
- Academy Funds (https://capitalatlas.ai/funds/academy-funds) — Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series B
- CDIB BioScience Venture Management (https://capitalatlas.ai/funds/cdib-bioscience-venture-management) — Series B
- Nomura Asset Management (https://capitalatlas.ai/funds/nomura-asset-management) — Series B
- Genavent — Series B
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series B
- Bison Capital Asset Management (https://capitalatlas.ai/funds/bison-capital-asset-management) — Series B
- Cogene Ventures (https://capitalatlas.ai/funds/cogene-ventures) — Series B
- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series B
- Rock Castle Ventures — Series B